|
RU2016143389A
(ru)
|
2014-04-10 |
2018-05-15 |
Сиэтл Чилдрен'С Хоспитал (Дба Сиэтл Чилдрен'С Ресёрч Инститьют) |
Получение генно-инженерных т-клеток посредством транспозона "спящая красавица" в сочетании с отбором метотрексатом
|
|
CN106536564B
(zh)
*
|
2014-06-02 |
2021-08-31 |
美国卫生和人力服务部 |
靶向cd-19的嵌合抗原受体
|
|
WO2016149578A1
(en)
|
2015-03-19 |
2016-09-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Dual specific anti-cd22-anti-cd19 chimeric antigen receptors
|
|
MX2018001568A
(es)
|
2015-08-07 |
2019-04-25 |
Seattle Children´S Hospital Dba Seattle Children´S Res Institute |
Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos.
|
|
WO2017070042A1
(en)
|
2015-10-20 |
2017-04-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of producing t cell populations using akt inhibitors
|
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
|
CN105906720A
(zh)
*
|
2016-05-16 |
2016-08-31 |
武汉汉密顿生物科技股份有限公司 |
靶向性嵌合抗原受体修饰的免疫细胞及其制备方法和应用
|
|
CN105949324B
(zh)
*
|
2016-06-30 |
2019-08-27 |
上海恒润达生生物科技有限公司 |
靶向gpc3的嵌合抗原受体及其用途
|
|
CN105949325B
(zh)
*
|
2016-07-08 |
2019-07-16 |
重庆精准生物技术有限公司 |
包含cd27胞内结构域的嵌合抗原受体、慢病毒载体及其应用
|
|
CN117298260A
(zh)
|
2016-09-02 |
2023-12-29 |
莱蒂恩技术公司 |
用DuoCAR治疗癌症的组合物和方法
|
|
US20190262399A1
(en)
|
2016-09-07 |
2019-08-29 |
The Broad Institute, Inc. |
Compositions and methods for evaluating and modulating immune responses
|
|
CN107936120B
(zh)
*
|
2016-10-13 |
2021-03-09 |
上海赛比曼生物科技有限公司 |
Cd19靶向性的嵌合抗原受体及其制法和应用
|
|
JP7288401B2
(ja)
|
2017-01-10 |
2023-06-07 |
プレシゲン，インコーポレイテッド |
新規の遺伝子スイッチ発現系を介したポリペプチドの発現のモジュレーション
|
|
WO2018183908A1
(en)
|
2017-03-31 |
2018-10-04 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating ovarian tumors
|
|
EP3606518A4
(en)
|
2017-04-01 |
2021-04-07 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR DETECTION AND MODULATION OF IMMUNOTHERAPY RESISTANCE GENE SIGNATURE IN CANCER
|
|
EP3610266A4
(en)
|
2017-04-12 |
2021-04-21 |
Massachusetts Eye and Ear Infirmary |
TUMOR SIGNATURE FOR METASTASIS, COMPOSITIONS OF MATERIAL AND THEIR METHODS OF USE
|
|
EP3622092A4
(en)
|
2017-05-11 |
2021-06-23 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF
|
|
US11622977B2
(en)
|
2017-05-12 |
2023-04-11 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
|
US11166985B2
(en)
|
2017-05-12 |
2021-11-09 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
|
CA3062433A1
(en)
|
2017-05-15 |
2018-11-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bicistronic chimeric antigen receptors and their uses
|
|
AU2018281316B2
(en)
|
2017-06-07 |
2024-05-30 |
Precigen, Inc. |
Expression of novel cell tags
|
|
EP3638218A4
(en)
|
2017-06-14 |
2021-06-09 |
The Broad Institute, Inc. |
COMPOSITIONS AND METHOD OF TARGETING COMPLEMENTING COMPONENT 3 FOR INHIBITION OF TUMOR GROWTH
|
|
WO2019014581A1
(en)
|
2017-07-14 |
2019-01-17 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE
|
|
US20200215112A1
(en)
*
|
2017-08-09 |
2020-07-09 |
Ctg Pharma Ltd. |
Chimeric antigen receptor for her2/neu and t-cells expressing same
|
|
US12043870B2
(en)
|
2017-10-02 |
2024-07-23 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
|
WO2019075055A1
(en)
|
2017-10-11 |
2019-04-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
METHODS FOR PRODUCING T-CELL POPULATIONS USING P38 MAPK INHIBITORS
|
|
WO2019084055A1
(en)
|
2017-10-23 |
2019-05-02 |
Massachusetts Institute Of Technology |
CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS
|
|
EP3710039A4
(en)
|
2017-11-13 |
2021-08-04 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH
|
|
WO2019094955A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas
|
|
EP3730519B1
(en)
*
|
2017-12-22 |
2023-09-13 |
AbClon Inc. |
Antibody or antigen-binding fragment thereof that specifically recognizes b cell malignancies, chimeric antigen receptor comprising same, and uses thereof
|
|
US11994512B2
(en)
|
2018-01-04 |
2024-05-28 |
Massachusetts Institute Of Technology |
Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
|
|
EP4656653A3
(en)
|
2018-02-09 |
2025-12-17 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Tethered interleukin-15 and interleukin-21
|
|
WO2019154313A1
(zh)
|
2018-02-11 |
2019-08-15 |
江苏恒瑞医药股份有限公司 |
一种分离的嵌合抗原受体以及包含其的修饰t细胞及用途
|
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
|
IL278348B2
(en)
*
|
2018-05-11 |
2025-03-01 |
Crispr Therapeutics Ag |
Methods and preparations for treating cancer
|
|
IL321548A
(en)
|
2018-05-22 |
2025-08-01 |
Immunitybio Inc |
Recombinant NK cells expressing a chimeric antigen receptor (CAR) for epsilon-FC and uses thereof
|
|
WO2019232542A2
(en)
|
2018-06-01 |
2019-12-05 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
|
US12036240B2
(en)
|
2018-06-14 |
2024-07-16 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
|
CN108841792A
(zh)
*
|
2018-06-14 |
2018-11-20 |
浙江大学 |
靶向cd19和ebna1基因修饰的t细胞及其制备方法与应用
|
|
CN108864307A
(zh)
*
|
2018-07-23 |
2018-11-23 |
北京多赢时代科技有限公司 |
信号肽优化靶向cd19的嵌合抗原受体、表达该嵌合抗原受体的t细胞及制备方法和应用
|
|
CN110819678A
(zh)
*
|
2018-08-07 |
2020-02-21 |
上海恒润达生生物科技有限公司 |
一种评估cart细胞有效性的方法
|
|
WO2020061048A1
(en)
*
|
2018-09-17 |
2020-03-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bicistronic chimeric antigen receptors targeting cd19 and cd20 and their uses
|
|
WO2020072700A1
(en)
|
2018-10-02 |
2020-04-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
|
WO2020081730A2
(en)
|
2018-10-16 |
2020-04-23 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating microenvironment
|
|
US20220170097A1
(en)
|
2018-10-29 |
2022-06-02 |
The Broad Institute, Inc. |
Car t cell transcriptional atlas
|
|
EP4578507A3
(en)
|
2018-11-01 |
2025-11-12 |
Gracell Biotechnologies (Shanghai) Co., Ltd. |
Compositions and methods for t cell engineering
|
|
CN111253487B
(zh)
*
|
2018-12-03 |
2024-02-02 |
广东东阳光药业股份有限公司 |
Cd19抗体及其应用
|
|
BR112021012172A2
(pt)
|
2018-12-12 |
2021-08-31 |
Kite Pharma, Inc. |
Receptores de antígenos quiméricos e de célula t e métodos de uso
|
|
US20220062394A1
(en)
|
2018-12-17 |
2022-03-03 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
|
CN109734813B
(zh)
*
|
2019-01-28 |
2022-06-17 |
广东昭泰体内生物医药科技有限公司 |
一种嵌合抗原受体及其应用
|
|
SG11202109057XA
(en)
|
2019-03-05 |
2021-09-29 |
Nkarta Inc |
Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
|
|
WO2020186101A1
(en)
|
2019-03-12 |
2020-09-17 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
|
RU2742000C2
(ru)
*
|
2019-03-13 |
2021-02-01 |
Общество С Ограниченной Ответственностью "Анабион" |
Выделенный альтернативный внутриклеточный сигнальный домен химерного антигенного рецептора и включающий его химерный антигенный рецептор
|
|
EP3942023A1
(en)
|
2019-03-18 |
2022-01-26 |
The Broad Institute, Inc. |
Compositions and methods for modulating metabolic regulators of t cell pathogenicity
|
|
EA202192975A1
(ru)
*
|
2019-04-30 |
2022-02-01 |
Криспр Терапьютикс Аг |
Аллогенная клеточная терапия b-клеточных злокачественных новообразований с применением генетически сконструированных т-клеток, нацеливающихся на cd19
|
|
JP7741732B2
(ja)
|
2019-05-07 |
2025-09-18 |
グレイセル・バイオテクノロジーズ（シャンハイ）カンパニー・リミテッド |
Ｂｃｍａを標的とする操作された免疫細胞及びその使用
|
|
US20220235340A1
(en)
|
2019-05-20 |
2022-07-28 |
The Broad Institute, Inc. |
Novel crispr-cas systems and uses thereof
|
|
CN114269372A
(zh)
*
|
2019-06-27 |
2022-04-01 |
克里斯珀医疗股份公司 |
嵌合抗原受体t细胞和nk细胞抑制剂用于治疗癌症的用途
|
|
US20220249565A1
(en)
*
|
2019-06-27 |
2022-08-11 |
Eutilex Co., Ltd. |
Chimeric antigen receptor with 4-ibb costimulatory domain
|
|
WO2020261231A1
(en)
*
|
2019-06-27 |
2020-12-30 |
Eutilex Co., Ltd. |
Chimeric antigen receptor with 4-1bb costimulatory domain
|
|
CN110305849B
(zh)
*
|
2019-08-01 |
2021-03-30 |
广东万海细胞生物科技有限公司 |
稳定表达car的t细胞及其制备方法与应用
|
|
US20220282333A1
(en)
|
2019-08-13 |
2022-09-08 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
|
US12421557B2
(en)
|
2019-08-16 |
2025-09-23 |
The Broad Institute, Inc. |
Methods for predicting outcomes and treating colorectal cancer using a cell atlas
|
|
US20220298501A1
(en)
|
2019-08-30 |
2022-09-22 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
|
US12297426B2
(en)
|
2019-10-01 |
2025-05-13 |
The Broad Institute, Inc. |
DNA damage response signature guided rational design of CRISPR-based systems and therapies
|
|
US12394502B2
(en)
|
2019-10-02 |
2025-08-19 |
The General Hospital Corporation |
Method for predicting HLA-binding peptides using protein structural features
|
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
|
US12195725B2
(en)
|
2019-10-03 |
2025-01-14 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
|
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
|
US11844800B2
(en)
|
2019-10-30 |
2023-12-19 |
Massachusetts Institute Of Technology |
Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
|
|
CN114929862A
(zh)
*
|
2019-11-13 |
2022-08-19 |
克里斯珀医疗股份公司 |
用于制备表达嵌合抗原受体的t细胞的生产方法
|
|
US12165747B2
(en)
|
2020-01-23 |
2024-12-10 |
The Broad Institute, Inc. |
Molecular spatial mapping of metastatic tumor microenvironment
|
|
CA3170369A1
(en)
|
2020-03-05 |
2022-04-14 |
Michal Shahar |
Methods and compositions for treating cancer with immune cells
|
|
CN113402612A
(zh)
|
2020-03-17 |
2021-09-17 |
西比曼生物科技（香港）有限公司 |
靶向cd19和cd20的联合嵌合抗原受体及其应用
|
|
US20230258635A1
(en)
|
2020-09-08 |
2023-08-17 |
The United States Of America,As Represented By The Secretary,Department Of Health And Human Services |
T cell phenotypes associated with response to adoptive cell therapy
|
|
US20240018210A1
(en)
|
2020-11-13 |
2024-01-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic |
Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain
|
|
WO2022133169A1
(en)
|
2020-12-18 |
2022-06-23 |
Century Therapeutics, Inc. |
Chimeric antigen receptor systems with adaptable receptor specificity
|
|
US20240316199A1
(en)
|
2020-12-30 |
2024-09-26 |
Alaunos Therapeutics, Inc. |
Recombinant Vectors Comprising Polycistronic Expression Cassettes and Methods of Use Thereof
|
|
WO2022165419A1
(en)
|
2021-02-01 |
2022-08-04 |
Kyverna Therapeutics, Inc. |
Methods for increasing t-cell function
|
|
WO2022180586A1
(en)
*
|
2021-02-25 |
2022-09-01 |
Senthil Natesan |
Car t-cell product and method of preparation thereof
|
|
CA3206951A1
(en)
|
2021-02-26 |
2022-09-01 |
Manel Esteller Badosa |
Markers of prediction of response to car t cell therapy
|
|
US20230046228A1
(en)
*
|
2021-07-26 |
2023-02-16 |
Crispr Therapeutics Ag |
Methods for manufacturing genetically engineered car-t cells
|
|
AU2022326908A1
(en)
*
|
2021-08-12 |
2024-03-28 |
Cellogen Therapeutics Pvt. Ltd. |
Chimeric antigen receptors (car) for b cell malignancies
|
|
CA3222263A1
(en)
|
2021-08-13 |
2023-02-16 |
Adrian GOTTSCHLICH |
Anti-csf1r car expressing lymphocytes for targeted tumor therapy
|
|
AU2022373657A1
(en)
*
|
2021-10-18 |
2024-05-16 |
Kite Pharma, Inc. |
Signaling domains for chimeric antigen receptors
|
|
WO2023130040A2
(en)
|
2021-12-31 |
2023-07-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
T cell therapy with vaccination as a combination immunotherapy against cancer
|
|
US20230210900A1
(en)
*
|
2022-01-04 |
2023-07-06 |
Kyverna Therapeutics, Inc. |
Methods for treating autoimmune diseases
|
|
WO2024040195A1
(en)
|
2022-08-17 |
2024-02-22 |
Capstan Therapeutics, Inc. |
Conditioning for in vivo immune cell engineering
|
|
EP4598949A1
(en)
|
2022-10-07 |
2025-08-13 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery of peptide-mhc targeting binding proteins
|
|
WO2024124044A1
(en)
|
2022-12-07 |
2024-06-13 |
The Brigham And Women’S Hospital, Inc. |
Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
|
|
AU2024213852A1
(en)
|
2023-01-30 |
2025-07-03 |
Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) |
Anti-cd86 car expressing lymphocytes for targeted tumor therapy
|
|
TW202502363A
(zh)
|
2023-02-28 |
2025-01-16 |
美商奇諾治療有限公司 |
用於治療全身性自體免疫疾病之細胞療法
|
|
US12311033B2
(en)
|
2023-05-31 |
2025-05-27 |
Capstan Therapeutics, Inc. |
Lipid nanoparticle formulations and compositions
|
|
WO2025006799A1
(en)
|
2023-06-27 |
2025-01-02 |
Capstan Therapeutics, Inc. |
Extracorporeal and ex vivo engineering of select cell populations from peripheral blood
|
|
WO2025049631A1
(en)
*
|
2023-08-28 |
2025-03-06 |
Kyverna Therapeutics, Inc. |
Allogeneic car-t cell therapies and manufacture thereof
|
|
WO2025059533A1
(en)
|
2023-09-13 |
2025-03-20 |
The Broad Institute, Inc. |
Crispr enzymes and systems
|
|
WO2025076127A1
(en)
|
2023-10-05 |
2025-04-10 |
Capstan Therapeutics, Inc. |
Constrained ionizable cationic lipids and lipid nanoparticles
|
|
WO2025076113A1
(en)
|
2023-10-05 |
2025-04-10 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids with conserved spacing and lipid nanoparticles
|
|
WO2025097055A2
(en)
|
2023-11-02 |
2025-05-08 |
The Broad Institute, Inc. |
Compositions and methods of use of t cells in immunotherapy
|
|
WO2025096878A1
(en)
|
2023-11-02 |
2025-05-08 |
Capstan Therapeutics, Inc. |
Rna for in vivo transfection with increased expression
|
|
WO2025117544A1
(en)
|
2023-11-29 |
2025-06-05 |
The Broad Institute, Inc. |
Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
|
|
WO2025129201A1
(en)
|
2023-12-15 |
2025-06-19 |
Capstan Therapeutics, Inc. |
Humanized anti-cd8 antibodies and uses thereof
|
|
WO2025147545A1
(en)
|
2024-01-03 |
2025-07-10 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids and related methods and uses
|
|
WO2025160480A1
(en)
|
2024-01-26 |
2025-07-31 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Enhanced tumor reactivity of t cells lacking sit1, lax1, or trat1
|
|
US20250302763A1
(en)
|
2024-02-22 |
2025-10-02 |
Capstan Therapeutics, Inc. |
Immune engineering amplification
|
|
WO2025217454A2
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles
|
|
WO2025217452A1
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Constrained ionizable cationic lipids and lipid nanoparticles
|
|
WO2025250587A1
(en)
|
2024-05-29 |
2025-12-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Drug-regulatable, inducible cytokine expression
|